mTOR inhibitors have recently been found to be effective for subependymal giant cell astrocytoma, renal angiomyolipoma, and pulmonary lymphangioleiomyomatosis, which are severe manifestations of TSC [9,16,17]. Here, MTOR is linked to tuberous sclerosis.